{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T21:07:16Z","timestamp":1784408836206,"version":"3.55.0"},"reference-count":13,"publisher":"Japan Surgical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2025]]},"DOI":"10.70352\/scrj.cr.25-0177","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T22:08:17Z","timestamp":1750975697000},"page":"n\/a","source":"Crossref","is-referenced-by-count":1,"title":["Immune Checkpoint Inhibitor-Related Aortitis Treated with Nivolumab for Esophageal Squamous Cell Carcinoma"],"prefix":"10.70352","volume":"11","author":[{"given":"Norihiro","family":"Akimoto","sequence":"first","affiliation":[{"name":"Department of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akikazu","family":"Yago","sequence":"additional","affiliation":[{"name":"Department of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Kasahara","sequence":"additional","affiliation":[{"name":"Department of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenki","family":"Segami","sequence":"additional","affiliation":[{"name":"Department of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Suwa","sequence":"additional","affiliation":[{"name":"Department of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakatsu","family":"Numata","sequence":"additional","affiliation":[{"name":"Department of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Kumamoto","sequence":"additional","affiliation":[{"name":"Department of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Surgery, Yokohama City University, Yokohama, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"51119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of immune-related adverse effects of immune checkpoint inhibitors: A review. JAMA Oncol 2016; 2: 1346\u201353.","DOI":"10.1001\/jamaoncol.2016.1051"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 1217\u201338.","DOI":"10.1016\/j.annonc.2022.10.001"},{"key":"3","unstructured":"3) Japanese Esophageal Society. Guidelines for the clinical and pathologic studies on carcinoma of the esophagus. 12th ed. Tokyo: Kanehara & Co. Ltd; 2022."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Sato S, Suzuki T, Chinen T, et al. Prognostic factors of second-line nivolumab monotherapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study for 184 cases. J Gastroenterol 2024; 59: 979\u201385.","DOI":"10.1007\/s00535-024-02141-8"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Sato S, Suzuki T, Chinen T, et al. The real-world data of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study. Int J Clin Oncol 2024; 29: 994\u20131001.","DOI":"10.1007\/s10147-024-02532-0"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Richter MD, Crowson C, Kottschade LA, et al. Rheumatic syndromes associated with immune checkpoint inhibitors: A single-center cohort of sixty-one patients. Arthritis Rheumatol 2019; 71: 468\u201375.","DOI":"10.1002\/art.40745"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Roy AK, Tathireddy HR, Roy M. Aftermath of induced inflammation: acute periaortitis due to nivolumab therapy. BMJ Case Rep 2017; 2017: bcr-2017-221852.","DOI":"10.1136\/bcr-2017-221852"},{"key":"8","unstructured":"8) Ban BH, Crowe JL, Graham RM. Rheumatology case report immune-related aortitis associated with ipilimumab. Rheumatologist 2017; 11: 5."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Bloomer CH, Annabathula RV, Aggarwal V, et al. A case report of Immune Checkpoint Inhibitor-Induced Aortitis Treated with tocilizumab. Case Reports Immunol 2022; 2022: 7971169.","DOI":"10.1155\/2022\/7971169"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2018; 36: 1714\u201368.","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Daxini A, Cronin K, Sreih AG. Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol 2018; 37: 2579\u201384.","DOI":"10.1007\/s10067-018-4177-0"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Boland P, Heath J, Sandigursky S. Immune checkpoint Inhibitors and vasculitis. Curr Opin Rheumatol 2020; 32: 53\u20136.","DOI":"10.1097\/BOR.0000000000000672"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Zhong H, Zhou J, Xu D, et al. Rheumatic immune-related adverse events induced by immune checkpoint inhibitors. Asia Pac J Clin Oncol 2021; 17: 178\u201385.","DOI":"10.1111\/ajco.13346"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/11\/1\/11_cr.25-0177\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T04:06:54Z","timestamp":1751083614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/11\/1\/11_cr.25-0177\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.25-0177","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"cr.25-0177"}}